SCHEMBL402875

SCHEMBL402875

[c]1ccc(SCc2ccccc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOA P21397 3/20 0.58
MAOB P27338 3/20 0.58
SLC6A4 P31645 1/20 0.49
POLB P06746 2/20 0.45
HSD17B10 Q99714 1/20 0.45
PPARG P37231 2/20 0.41
PPARA Q07869 2/20 0.41
HAO1 Q9UJM8 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
DAO P14920 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPK1 P28482 1/20 0.41
LTA4H P09960 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1712262 0.91 MAOA (0.53) MAOAMAOBSLC6A4POLBHSD17B10
SCHEMBL8745139 0.89 MAOB (0.44) MAOAMAOBSLC6A4POLBHSD17B10
SCHEMBL332623 0.84 MAOA (0.63) MAOAMAOBSLC6A4POLBHSD17B10
SCHEMBL28084553 0.81 MAOA (0.61) MAOAMAOBSLC6A4POLBHSD17B10
SCHEMBL4612754 0.81 MAOA (0.59) MAOAMAOBHSD17B10KDM4EMEN1
SCHEMBL694538 0.79 MEN1 (0.61) MAOAMAOBMEN1KMT2ADAO
SCHEMBL28938496 0.79 MAOB (0.38) MAOAMAOBSLC6A4POLBHSD17B10
SCHEMBL10055053 0.79 ALDH1A1 (0.57) MAOAMAOBSLC6A4POLBHSD17B10
SCHEMBL442875 0.78 MAOA (0.49) MAOAMAOBSLC6A4POLBHSD17B10
SCHEMBL694551 0.77 DAO (0.50) MAOBMEN1KMT2ADAOALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 518 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220073461-A1 (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES WARSZAWSKI UNIWERSYTET MEDYCZNY (PL) 2022-03-10 US claimed
EP-3908580-A1 (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES UNIWERSYTET JAGIELLONSKI (PL) 2021-11-17 EP claimed
WO-2020145831-A1 (2,5-DIOXOPYRROLIDIN-L-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES Uniwersytet Jagielloński (PL) 2020-07-16 WO claimed
WO-2019170046-A1 GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海来益生物药物研究开发中心有限责任公司 2019-09-12 WO claimed
US-10294246-B2 Substituted boronic acids and boronate esters as immunoproteasome inhibitors MERCK PATENT GMBH (DE) 2019-05-21 US claimed
CN-104181772-B Two-photon activity photo-acid agent of the one kind using biphenyl as conjugated structure, preparation method and applications 同济大学 2018-07-03 CN claimed
CN-104238268-B Sulfosalt class photo-acid agent based on triphenylethylene, preparation method and applications 同济大学 2017-12-26 CN claimed
CN-105712917-B Conjugated type sulfosalt light trigger, preparation method and applications with light trigger and photosensitizer dual-use function 同济大学 2017-12-26 CN claimed
US-9051296-B2 Aryl carboxamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-06-09 US claimed
CN-104238268-A Sulfonium salt photoacid generator adopting triphenylethylene as main body, preparation method of sulfonium salt photoacid generator and application of sulfonium salt photoacid generator UNIV TONGJI 2014-12-24 CN claimed
US-20050070624-A1 Arylsulfinate salts in photoinitiator systems for polymerization reactions 3M INNOVATIVE PROPERTIES COMPANY 2005-03-31 US claimed
US-20050070622-A1 Arylsulfinate salts in initiator systems for polymeric reactions 3M INNOVATIVE PROPERTIES COMPANY 2005-03-31 US claimed
US-20040132758-A1 Modulators of the glucocorticoid receptor and method BRISTOL-MYERS SQUIBB COMPANY 2004-07-08 US claimed
JP-2004505014-A 2004-02-19 JP claimed
WO-2004009017-A2 MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-29 WO claimed
EP-1268463-A2 POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 4-PYRONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE Pharmacia Corporation (US) 2003-01-02 EP claimed
WO-2001087852-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE PHARMACIA CORPORATION (US) 2001-11-22 WO claimed
WO-2001077097-A2 POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 4-PYRONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE PHARMACIA CORPORATION (US) 2001-10-18 WO claimed
WO-2001068605-A1 POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED BENZENES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE PHARMACIA CORPORATION (US) 2001-09-20 WO claimed
EP-0542556-B1 Thermosensitive recording material NEW OJI PAPER CO LTD (JP) 1995-07-19 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073461-A1 (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES TRPV5, P2RX5, TRPV1 MAOA 301/4885MAOB 519/4885SLC6A4 2147/4885
US-10294246-B2 Substituted boronic acids and boronate esters as immunoproteasome inhibitors PSMB7, PSMA7, PSMB11 MAOA 3594/4885MAOB 2500/4885SLC6A4 4747/4885
US-20040132758-A1 Modulators of the glucocorticoid receptor and method NR3C1, NR3C2, MC2R MAOA 3269/4885MAOB 2565/4885SLC6A4 4474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.